Evidence map›Paper›PMID 42719222›Full record

ArticleFrontiers in aging2026

Repurposing MK0873 as a non-covalent hTERT-Targeting compound: a proof of concept study.

Maham Ansari, Abdul Wali, Mohhamed Rasul, Kristina Gemzell Danielsson, Twana Alkasalias, Muhammad Mushtaq

Abstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Frontiers in aging, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

6 authors.

Maham AnsariDepartment of Biotechnology, Faculty of Life Sciences and Informatics, Balochistan University of Information Technology, Engineering and Management Sciences (BUITEMS), Quetta, Pakistan.
Abdul WaliDepartment of Biotechnology, Faculty of Life Sciences and Informatics, Balochistan University of Information Technology, Engineering and Management Sciences (BUITEMS), Quetta, Pakistan.
Mohhamed RasulDepartment of Women's and Children's Health Karolinska Institutet, Stockholm, Sweden.
Kristina Gemzell DanielssonDepartment of Women's and Children's Health Karolinska Institutet, Stockholm, Sweden.
Twana AlkasaliasDepartment of Women's and Children's Health Karolinska Institutet, Stockholm, Sweden.
Muhammad MushtaqDepartment of Biotechnology, Faculty of Life Sciences and Informatics, Balochistan University of Information Technology, Engineering and Management Sciences (BUITEMS), Quetta, Pakistan.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Telomerase is a key regulator of both cellular immortality and aging, making it an attractive target for cancer therapy and age associated pathologies. Its clinical exploitation has been limited by structural complexity and challenges in achieving specificity. Recent structural insights into human telomerase reverse transcriptase (hTERT) have enabled the identification of selective inhibitors. Here, we repurposed MK0873, a PDE4 inhibitor previously evaluated in Phase II clinical trials for rheumatoid arthritis and COPD, as a non covalent telomerase targeting agent.

Indexed as

cellular senescencedrug repurposingMK0873neuroblastomatelomerase inhibition

Identifiers

PMID42719222
PMCPMC13553947

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.